title: The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes.
abstract: BACKGROUND
  Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of antihyperglycemic drugs that block degradation ofincretin hormones.
  
  
  OBJECTIVE
  To assess the effects oftreatment with DPP-4 inhibitors on glucoregulation and body weight in obese patients with type 2 diabetes mellitus.
  
  
  METHODS
  The study included 9 females and 9 males with type 2 diabetes (n=18), BMI=31.24 +/- 2,26 kg/m2, mean age 58 +/- 6,8 years. The patients have been thoroughly evaluated before treatment, and 6 months after treatment with DPP-4 inhibitor (sitagliptin) in combination with metformin.
  
  
  RESULTS
  After 6 months of treatment with DPP-4 inhibitors in combination with metformin HbAlc (-1,49%)., FBG (-3.75 mmol/L) and PBG (-5.79 mmol/L) significantly reduced (p=0.000). Mean body weight also significantly reduced (-12.5%; p=0.000). Reduction of mean fasting insulin was 5.46 mIU/L or 27% (p=0.000). Mean HOMA-IR change was -1.64 (p=0.000). Also there was significant decreasing of systolic blood pressure (p=0.001), cholesterol (p=0.004), triglycerides (p=0.001), LDL (p=0.002) and increasing of HDL (p=0.002). Hypoglycaemia was not registered in any of the patients.
  
  
  CONCLUSIONS
  These results show that in obese patients with type 2 diabetes, DPP-4 inhibitors treatment in combination with metformin was associated with improvements in glycaemic control, and a reduction in body weight.
authors.affiliation: Clinic of Endocrinology, Diabetes and Metabolism diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina. zelijav@gmail.com
authors.forename: Zelija
authors.initials: Z
authors.lastname: Velija-Asimi
authors.affiliation: General Hospital "Prim. Dr Abdulah Nakas", Sarajevo, Bosnia and Herzegovina.
authors.forename: Sebija
authors.initials: S
authors.lastname: Izetbegovic
authors.affiliation: Department of Clinical Immunology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Jasenko
authors.initials: J
authors.lastname: Karamehic
authors.affiliation: Clinic for Clinical Biochemistry, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Jozo
authors.initials: J
authors.lastname: Coric
authors.affiliation: Clinic for Clinical Biochemistry, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Mirsad
authors.initials: M
authors.lastname: Panjeta
authors.affiliation: General Hospital "Prim. Dr Abdulah Nakas", Sarajevo, Bosnia and Herzegovina.
authors.forename: Amra
authors.initials: A
authors.lastname: Macic-Dzankovic
authors.affiliation: Clinic of Neurology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Jasminka
authors.initials: J
authors.lastname: Djelilovic-Vranic
authors.affiliation: Clinic of Endocrinology, Diabetes and Metabolism diseases, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
authors.forename: Amela
authors.initials: A
authors.lastname: Dizdarevic-Bostandzic
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose; D001794:Blood Pressure; D015992:Body Mass Index; D001835:Body Weight; D008078:Cholesterol, LDL / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D008078:Cholesterol, LDL; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D011719:Pyrazines; D000068900:Sitagliptin Phosphate; D014230:Triazoles; D014280:Triglycerides; C517652:hemoglobin A1c protein, human